Europe Genome Editing Market Size & Outlook, 2023-2030
Europe genome editing market, 2018-2030 (US$M)
Related Markets
Europe genome editing market highlights
- The Europe genome editing market generated a revenue of USD 2,260.8 million in 2023.
- The market is expected to grow at a CAGR of 18.5% from 2024 to 2030.
- In terms of segment, (crispr)/cas9 was the largest revenue generating technology in 2023.
- (CRISPR)/Cas9 is the most lucrative technology segment registering the fastest growth during the forecast period.
- Country-wise, Italy is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 2,260.8 million |
| Market revenue in 2030 | USD 7,399.1 million |
| Growth rate | 18.5% (CAGR from 2023 to 2030) |
| Largest segment | (crispr)/cas9 |
| Fastest growing segment | (CRISPR)/Cas9 |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, Meganuclease |
| Key market players worldwide | Merck KGaA, Cibus Inc Ordinary Shares - Class A, Recombinetics, Sangamo Therapeutics Inc, Editas Medicine Inc, Precision BioSciences Inc, CRISPR Therapeutics AG, Intellia Therapeutics Inc, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, AstraZeneca PLC, Takara Bio Inc, Horizon Discovery, Danaher Corp, Genscript Biotech Corp Class H, New England Biolabs, Origene Technologies, Bluebird bio Inc, Lonza Group Ltd, Thermo Fisher Scientific Inc |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.4% of the global genome editing market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,743.8 million by 2030.
(crispr)/cas9 was the largest segment with a revenue share of 44.6% in 2023. Horizon Databook has segmented the Europe genome editing market based on (crispr)/cas9, talens/megatals, zfn, meganuclease covering the revenue growth of each sub-segment from 2018 to 2030.
The UK genome editing market presents several potential opportunities that favor an increase in the usage of advanced genome editing tools. Numerous efforts undertaken by UK-based genome editing companies and funding initiatives supported by private & public entities drive the UK genome editing market.
For instance, in February 2021, Horizon Europe was anticipated to award USD 5.8 million for projects to understand the risks and benefits of genome editing technology in the agriculture sector over the next 2 years.
In December 2020, Horizon Discovery granted two commercial licenses to Sanyou Biopharmaceuticals for its cGMP compliant CHOSOURCE platform. Sanyou was expected to utilize Horizon’s gene-edited CHO-K1 GS knockout cell line in contract research and development services and biotherapeutics pipeline development.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Genome Editing Market Scope
Genome Editing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe genome editing market size, by country, 2018-2030 (US$M)
Europe Genome Editing Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
